Publicaciones en colaboración con investigadores/as de Hospital General Universitario Gregorio Marañón (20)

2023

  1. Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer (npj Breast Cancer, (2021), 7, 1, (1), 10.1038/s41523-020-00208-2)

    npj Breast Cancer

2021

  1. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

    npj Breast Cancer, Vol. 7, Núm. 1

2019

  1. Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement

    Oncologist, Vol. 24, Núm. 5, pp. 603-611

2018

  1. Correction to: Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling (Breast Cancer Research and Treatment, (2018), 171, 3, (627-634), 10.1007/s10549-018-4855-2)

    Breast Cancer Research and Treatment

  2. Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling

    Breast Cancer Research and Treatment, Vol. 171, Núm. 3, pp. 627-634

2016

  1. Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile

    Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428

  2. Quality indicators to assure and improve cancer care in Spain using the delphi technique

    JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, Núm. 5, pp. 553-558

  3. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature

    Critical Reviews in Oncology/Hematology, Vol. 97, pp. 96-106

2014

  1. Predicting response and survival in chemotherapy-treated triple-negative breast cancer

    British Journal of Cancer, Vol. 111, Núm. 8, pp. 1532-1541

2013

  1. Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 13, Núm. 3, pp. 381-391

  2. Genetic variants in PARP1 (rs3219090) and IRF4 (rs12203592) genes associated with melanoma susceptibility in a Spanish population

    BMC Cancer, Vol. 13

2012

  1. MC1R, SLC45A2 and TYR genetic variants involved in melanoma susceptibility in Southern European populations: Results from a Meta-analysis

    European Journal of Cancer, Vol. 48, Núm. 14, pp. 2183-2191

  2. Prospective transGEICAM study of the impact of the 21-gene recurrence score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer

    Annals of Oncology, Vol. 23, Núm. 3, pp. 625-631

  3. Role of glutathione S-transferases in melanoma susceptibility: Association with GSTP1 rs1695 polymorphism

    British Journal of Dermatology, Vol. 166, Núm. 6, pp. 1176-1183

2011

  1. A customized pigmentation snp array identifies a novel snp associated with melanoma predisposition in the slc45a2 gene

    PLoS ONE, Vol. 6, Núm. 4

  2. Genetic polymorphisms in DNA repair and oxidative stress pathways associated with malignant melanoma susceptibility

    European Journal of Cancer, Vol. 47, Núm. 17, pp. 2618-2625

2010

  1. Adjuvant docetaxel for high-risk, node-negative breast cancer

    New England Journal of Medicine, Vol. 363, Núm. 23, pp. 2200-2210

  2. Practical prognostic index for patients with metastatic recurrent breast cancer: Retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register

    Breast Cancer Research and Treatment, Vol. 122, Núm. 2, pp. 591-600

  3. Supportive care for patients with early breast cancer

    Clinical and Translational Oncology, Vol. 12, Núm. 1, pp. 32-42

2009

  1. Guidelines for HER2 testing in breast cancer. A national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Revista Espanola de Patologia, Vol. 42, Núm. 1, pp. 3-16